SI2401272T1 - Amorfna sol makrocikličnega inhibitorja VHC - Google Patents

Amorfna sol makrocikličnega inhibitorja VHC

Info

Publication number
SI2401272T1
SI2401272T1 SI201031402A SI201031402A SI2401272T1 SI 2401272 T1 SI2401272 T1 SI 2401272T1 SI 201031402 A SI201031402 A SI 201031402A SI 201031402 A SI201031402 A SI 201031402A SI 2401272 T1 SI2401272 T1 SI 2401272T1
Authority
SI
Slovenia
Prior art keywords
hcv
amorphous salt
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
SI201031402A
Other languages
English (en)
Inventor
Remoortere Peter Jozef Maria Van
Roger Petrus Gerebern Vandecruys
Kock Herman De
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2401272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of SI2401272T1 publication Critical patent/SI2401272T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
SI201031402A 2009-02-27 2010-02-26 Amorfna sol makrocikličnega inhibitorja VHC SI2401272T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09153964 2009-02-27
EP10706539.3A EP2401272B1 (en) 2009-02-27 2010-02-26 Amorphous salt of a macrocyclic inhibitor of hcv
PCT/EP2010/001197 WO2010097229A2 (en) 2009-02-27 2010-02-26 Amorphous salt of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number Publication Date
SI2401272T1 true SI2401272T1 (sl) 2017-04-26

Family

ID=40756982

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031402A SI2401272T1 (sl) 2009-02-27 2010-02-26 Amorfna sol makrocikličnega inhibitorja VHC

Country Status (26)

Country Link
US (2) US9321758B2 (sl)
EP (2) EP3150596A1 (sl)
JP (2) JP5711672B2 (sl)
KR (2) KR101868412B1 (sl)
CN (2) CN104478868A (sl)
AU (1) AU2010219160B2 (sl)
BR (1) BRPI1008918A2 (sl)
CA (2) CA2898529C (sl)
CY (1) CY1119121T1 (sl)
DK (1) DK2401272T3 (sl)
ES (1) ES2616603T3 (sl)
HK (2) HK1166315A1 (sl)
HR (1) HRP20170214T1 (sl)
HU (1) HUE031738T2 (sl)
IL (2) IL214398A0 (sl)
LT (1) LT2401272T (sl)
MX (1) MX340792B (sl)
NZ (1) NZ594403A (sl)
PL (1) PL2401272T3 (sl)
PT (1) PT2401272T (sl)
RU (1) RU2536868C2 (sl)
SG (2) SG173772A1 (sl)
SI (1) SI2401272T1 (sl)
SM (1) SMT201700121B (sl)
WO (1) WO2010097229A2 (sl)
ZA (1) ZA201106303B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
SG173772A1 (en) * 2009-02-27 2011-09-29 Ortho Mcneil Janssen Pharm Amorphous salt of a macrocyclic inhibitor of hcv
US9034832B2 (en) * 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
CN104780921A (zh) * 2012-08-31 2015-07-15 杨森制药公司 Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA116237C2 (uk) * 2013-03-15 2018-02-26 Бьорінгер Інгельхайм Інтернаціональ Гмбх Тверда пероральна дозована композиція інгібітору нсv в аморфному стані
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015109925A1 (zh) * 2014-01-21 2015-07-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2015180253A1 (zh) * 2014-05-29 2015-12-03 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2016054240A1 (en) * 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
WO2017017604A1 (en) 2015-07-27 2017-02-02 Lupin Limited Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
CN1889970B (zh) * 2003-10-14 2012-06-13 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
RU2006133842A (ru) * 2004-02-24 2008-03-27 Зигфрид Дженерикс Интерэшнл Аг (Ch) Фармакологически приемлемые соли клопидогрела
UA91677C2 (ru) * 2004-03-30 2010-08-25 Интермюн, Инк. Макроциклические соединения как ингибиторы вирусной репликации
EA012389B1 (ru) 2004-03-30 2009-10-30 Интермун, Инк. Макроциклические соединения в качестве ингибиторов вирусной репликации
EP1831171A4 (en) * 2004-11-19 2010-09-15 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2008115173A (ja) 2006-10-13 2008-05-22 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体
US8399434B2 (en) 2006-11-08 2013-03-19 Duke University Method of activation of oxazaphosphorines
CL2008000321A1 (es) * 2007-02-01 2008-08-22 Tibotec Pharm Ltd Compuesto macrociclo en forma cristalina, inhibidor del virus de la hepatitis c (vhc); mezcla de una o mas formas cristalinas; procesos de preparacion de las formas cristalinas; y composicion farmaceutica que las comprende.
CN105111200A (zh) * 2007-02-01 2015-12-02 爱尔兰詹森科学公司 用于制备hcv的大环蛋白酶抑制剂的方法和中间体
MX2010002300A (es) 2007-08-29 2010-03-18 Pfizer Prod Inc Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
SG173772A1 (en) * 2009-02-27 2011-09-29 Ortho Mcneil Janssen Pharm Amorphous salt of a macrocyclic inhibitor of hcv

Also Published As

Publication number Publication date
US20110306634A1 (en) 2011-12-15
KR101713066B1 (ko) 2017-03-07
EP2401272B1 (en) 2017-01-11
RU2011139325A (ru) 2013-04-10
JP2015143240A (ja) 2015-08-06
ES2616603T3 (es) 2017-06-13
SMT201700121B (it) 2017-03-08
HK1166315A1 (en) 2012-10-26
CA2898529A1 (en) 2010-09-02
AU2010219160A1 (en) 2011-08-25
JP5711672B2 (ja) 2015-05-07
LT2401272T (lt) 2017-03-27
DK2401272T3 (en) 2017-02-27
SG173772A1 (en) 2011-09-29
AU2010219160B2 (en) 2015-12-10
CN104478868A (zh) 2015-04-01
RU2536868C2 (ru) 2014-12-27
NZ594403A (en) 2013-07-26
US20160251345A1 (en) 2016-09-01
BRPI1008918A2 (pt) 2016-03-15
JP6214584B2 (ja) 2017-10-18
US9321758B2 (en) 2016-04-26
WO2010097229A2 (en) 2010-09-02
IL214398A0 (en) 2011-09-27
EP3150596A1 (en) 2017-04-05
KR101868412B1 (ko) 2018-06-18
CA2753667C (en) 2015-11-17
CA2753667A1 (en) 2010-09-02
SG2014008981A (en) 2014-04-28
JP2012519158A (ja) 2012-08-23
CN102356080B (zh) 2015-04-29
MX2011008999A (es) 2011-09-26
PT2401272T (pt) 2017-02-28
PL2401272T3 (pl) 2017-06-30
CA2898529C (en) 2017-10-17
KR20110123273A (ko) 2011-11-14
IL243058A0 (en) 2016-02-29
HK1208464A1 (en) 2016-03-04
CN102356080A (zh) 2012-02-15
WO2010097229A3 (en) 2010-11-11
CY1119121T1 (el) 2018-02-14
MX340792B (es) 2016-07-25
HUE031738T2 (en) 2017-07-28
HRP20170214T1 (hr) 2017-04-07
ZA201106303B (en) 2013-02-27
KR20170026660A (ko) 2017-03-08
EP2401272A2 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
HRP20170214T1 (hr) Amorfna sol makrocikličkog inhibitora hcv
HUS000511I2 (hu) Gilteritinib vagy sója
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
EP2410841A4 (en) SUBSTITUTED BICYCLIC HCV INHIBITORS
IL216648A0 (en) Crystalline forms of febuxostat
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
AP3079A (en) A slush
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
IL215315A0 (en) Solid state forms of sitagliptin salts
AP3169A (en) A method of improved positioning
SG10201408584UA (en) Crystalline Methylthionium Chloride Hydrates
EP2504343A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
PL2301943T3 (pl) Krystalizacja epidaunorubicyny x HCI
PL2333462T3 (pl) Trzy postacie lodu z pojedynczego wgłębienia
AP2013006733A0 (en) Solid state forms of a potent HCV inhibitor
HK1169314A1 (zh) δ-生育酚-碳水化合物作為脫色劑的用途
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
GB2458027B (en) A method of selection
GB0904499D0 (en) A set of parts
GB0903651D0 (en) Inhibitors of glyoxalase
GB0919237D0 (en) Improvements of a device
GB0902782D0 (en) Disposal of metal salts
SI2398784T1 (sl) Kristalna oblika febuksostata
GB0906919D0 (en) Inhibitor complex structure